The International Pharmaceutical Aerosol Consortium congratulates the Montreal Protocol Parties on 30 years of progress in ozone healing.Learn More
IPAC-RS has submitted comments on USP the Stimulus Article “Proposals for Data Interpretation in the Context of Determination of Aerodynamic Particle Size Distribution Profile for Orally Inhaled Products.”Learn More
IPAC-RS has submitted comments to EMA on two recent concept papers.Learn More
The Cascade Impaction WG’s paper about results of the second IPAC-RS experiment on discriminating ability of AIM and EDA has been published by AAPS PharmSciTech.Learn More
No Upcoming IPAC-RS Events
The European Medicines Agency recently finalized a Guideline on the clinical investigation of medicinal products for the treatment of asthma. The guideline will be effective May 1, 2016. The current version of the guideline includes a section on the treatment of asthma in children, some considerations for the development of immunotherapy, and focuses on control-based management of the disease.
In a recent press briefing, EMA Executive Director Guido Rasi discussed his vision for the next five years. Dr. Rasi emphasized EMA’s commitment to transparency, patient involvement, and research and development for medicines that address public health needs. He also stressed the importance of strong cooperation between the member states, the European Commission, and other international partners.
The American National Standards Institute (ANSI) publically released its comments on the on the draft Chinese national standard “Association Standardization—Part 1: Guidelines for Good Practice.” The ANSI comments recommend that Chinese associations be required to open participation in the standards development process to all stakeholders and encourages Chinese associations to practice transparency during the development process.
New Zealand has updated its labeling guidance to include MHRA guidance published in 2014 as a best practice document for guidance on labelling and packaging of medicines.Learn More
The leader of the China Food and Drug Administration (CFDA), Bi Jingquan, has endorsed legislation reforming the drug approval process that would incentivize research and improve generic drug quality.
The CFDA has also issued guidance on the quality and efficacy of generic medicines for public feedback. According to RAPS, the draft document includes sections on the need for CFDA to retool its operation to oversee the consistent evaluation of generic filings and a call for a government-wide shift in approach to the sector.
Become an IPAC-RS member today Participation in IPAC-RS affords a variety of benefits including opportunities to shape the scientific and regulatory environment and tools to stay informed.